Oral Therapies in Psoriasis Management: A Debate on Deucravacitinib vs Apremilast - Episode 7
Practical Considerations for Using Oral Psoriasis Therapies in Practice
Panelists discuss how practical factors such as dosing, monitoring, and patient preference shape optimal use of oral psoriasis therapies.
Panelists discuss how selecting between deucravacitinib and apremilast involves weighing indication scope, dosing simplicity, and monitoring needs. Deucravacitinib’s once-daily oral regimen enhances convenience, while apremilast’s broad indications and minimal lab monitoring make it suitable for varied patient types.
Panelists discuss how adherence and satisfaction improve when therapy aligns with patient lifestyle. They highlight the importance of discussing expectations around efficacy and adverse effects, ensuring that patients remain engaged and informed. Personalization extends beyond clinical data to shared decision-making in everyday practice.
Panelists discuss how clinicians can leverage patient preference, comorbidity assessment, and psychosocial context to choose the most appropriate therapy. This collaborative approach fosters trust, enhances adherence, and optimizes long-term outcomes.
